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Systemic thickening of capillary endothelial basement membrane underlies the chronic complications of human
diabetic microangiopathy. Since 99mTc-DTPA aerosol scintigraphy is a sensitive, non-invasive test of membrane
permeability, we decided to study the effect of diabetes on the permeability of lung epithelium in diabetic patients
using this test.
Fifty (NIDDM) patients, aged 40–70 years, with or without complications, and who were non-smokers, were
subjected to evaluation using 99mTc-DTPA aerosol. At the same time, pulmonary function tests, including carbon
monoxide diffusion capacity, were done. Normal non-smoking subjects with no history of cardio-respiratory
disease, who underwent 99mTc-DTPA and pulmonary function tests, served as controls. The risk factors which
included age, sex, degree of control and presence of complications were noted.
Twenty-nine (58%) of the patients had abnormal 99mTc-DTPA clearance. Thirty-four percent of the patients
with complications and 24% of those without complications had abnormal clearance. Complications recorded
included retinopathy, neuropathy and nephropathy.
Fifty-five percent of patients with abnormal 99mTc-DTPA had suffered from diabetes for longer than 10 years.
Sixty-two percent of patients with poor glycaemic control had abnormal 99mTc-DTPA. Diffusion capacity was not
significantly affected in patients with complicated diabetes.
Our preliminary results suggest that 99mTc-DTPA is a potentially sensitive test in assessing the degree of lung
affection in diabetic patients. No significant correlation exists between diffusion capacity and 99mTc-DTPA. The
risk factors did not affect the 99mTc-DTPA clearance, probably due to the small sample size.
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Systemic thickening of capillary endothelial basement
membranes underlies the chronic complication of human
diabetic microangiopathy. Affected blood vessels have
markedly thickened and split basement membranes with a
laminar arrangement around endothelial cells and peri-
cytes. Hyperglycaemia induced glycosylation is a major
pathogenic factor in basement membrane thickening (1).
The vascular changes may lead to complications such as
blindness, renal failure and gangrene of extremities.Received 31 January 2000 and accepted in revised form 9 June
2000. Published online 12 September 2000.
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0954-6111/00/111053+04 $35?00/0Microvascular changes in a particular vascular bed such
as muscle do not correlate well with the presence or absence
of clinical microangiopathy in other tissues such as kidney
(2), indicating the importance of the ability to diagnose the
effect of diabetes on each site independently, including the
lungs.
Diabetes might be present long before it is diagnosed,
and the microvascular changes may start even before the
disease is clinically evident (4).
Silent impairment of the microvascular function occurs
with increased disease duration. Patients who have had
diabetes for 10–15 years, regardless of the type, are known
to develop microangiopathy.
On the other hand additional factors may be involved in
the pathogenesis of diseases affecting diabetics (especially
chest infections) since their normal response to stress is
attenuated (3). Microvascular complications cause a
decreased oxygen supply to the tissue leading to increased
incidence of infection (3). In addition, the increased content# 2000 HARCOURT PUBLISHERS LTD
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the release of oxygen into tissue. The decreased blood
supply in turn reduces the supply of white blood cells
(WBCs) to the affected area (3). Another reason is that the
function of the WBC itself is affected in such patients
(abnormal chemotaxis and phagocytosis)
Since little is known in the literature regarding lung
involvement in diabetes, and since technetium 99m-
diethyltriaminepentaaceticacid ( 99mTc-DTPA) aerosol scin-
tigraphy is a sensitive (5), non-invasive and readily
available test of the membrane permeability (6) we planned
to study the permeability of lung epithelium in diabetic
patients, using technetium 99m aerosol, and to test the
various factors that might affect it.
Materials and methods
A total of 50 patients (26 males and 24 females) were
included in the study. The age range was 40–75 years with a
mean of 53?53 years .
All patients were either life-long non-smokers or had quit
smoking at least 15 years prior to enrolment in the study.
All patients were non-insulin dependent diabetics
(NIDDM). All the patients had no past or present history
of any pulmonary disease. None of them was taking any
drugs other than the treatment for diabetes.
Diabetic control was evaluated by either the mean blood
sugar estimation over the last 12 months (good control,
blood sugar up to 7?5mmol/l or poor control) or by
haemoglobin A1c estimation. The patients were screened
for diabetic complications (retinopathy, neuropathy and
nephropathy) based on clinical and laboratory findings
(urine routine and microscopy, fundoscopy and nerve
conduction study).
All 50 patients had full pulmonary function testing using
a Jager master lab. The Spirometric parameters, volumes
and single breath carbon monoxide diffusion capacity
(transfer factor) were estimated. The pulmonary function
testing was done in one laboratory by one technician. One
pulmonary physician interpreted all the results. The
technician and the interpreting physician were blinded to
the patients clinical data and whether patients were
included in the study or not.
The 99mTc-DTPA aerosol studies were performed using
35mCi (35637MBq) in the reservoir. The aerosol was
delivered through an ultrafine nebulizer (Venti-Scan III
disposable Radioaerosol kit [#177–080] Biodex, Shirely,
NY, U.S.A.) with an oxygen flow of 8 to 10 lmin71
resulting in a particle size of 2–5 mm. All patients, while in a
sitting position, inhaled the generated 99mTc-DTPA aero-
sols for 5min. Using a large field of view camera equipped
with a low energy general purpose collimator, dynamic
imaging was acquired in 30 sec frames for 60min over the
posterior view on a matrix size of 64664.
Regions of interest over each lung, from the composite of
all dynamic reframed images, were drawn. Regions of
interest were also drawn over the shoulder for background
correction. Time activity curves were then generated and t
value of the clearance of the radioaerosol of each lung wasdetermined and the mean value for both lungs was
calculated. Values of t
99mTc-DTPA aerosol clearance
were compared to the normal values of our laboratory (7).
Significantly higher or lower values than our normal
laboratory values of 61?5+ 3?95min (for adult, normal
and non-smokers) were considered abnormal. Our normal
control values are in agreement with those reported by
Barbara et al. (8) and Jones et al. (9).
STATISTICAL ANALYSIS
To study the correlation of different risk factors (age, type
of diabetes, control pattern, presence or absence of
complication, etc) with the results of DTPA clearance from
the lungs of diabetics a w2-test was used to detect the
proportion of the abnormality in groups in relation to the
presence or absence of the risk factor. Multivariate analysis
and logistic regression was used to evaluate the risk of each
factor independently for the delay of DTPA clearance from
the lung by adjusting the influence of the rest of the factors.
Results
The total number of the sample was 50 patients. There were
26 (52%) males and 24 (48%) females. The age ranged
between 40 and 75 years (a mean of 53?53 years). Twenty-
one (42%) patients had good diabetic control and 29 (58%)
patients had poor control. Thirty-one (62%) patients had
one or more complications and 19 (38%) had none.
Twenty-five (50%) patients had neuropathy, 25 (50%)
patients had retinopathy and 22 (44%) patients had
nephropathy. Thirty-two (64%) patients were taking oral
medications only while 18 (36%) patients were taking
insulin alone or in combination with oral treatment.
Among all patients, 29 (58%) patients had delayed
DTPA clearance from the lungs. Table 1 shows the
patients’ characteristics in relation to DTPA clearance.
Table 2 shows the summary of clinical parameters
of patients with abnormal DTPA clearance. Table 3
shows the relationship of the presence or absence of
diabetic complications (total and stratified) to the DTPA
clearance.
The odds ratio of each risk factor, independent of the
other factors, to the values of DTPA clearance was also
determined in a multivariate analysis (Table 4). None of the
risk factors reached statistical significance in relation to the
independent effect on the DTPA clearance from the lungs.
On the other hand the risk factor was found to be higher for
those patients with established retinopathy (odds ratio of
9?2), and lower in males and patients with good diabetic
control and in those patients without any of the diabetic
complications (odds ratio of 0?37, 0?79 and 0?36 respec-
tively)
The pulmonary function tests (spirometric parameters,
volumes and carbon monoxide diffusion capacity) were
studied also and none of them showed a significant
relationship to the DTPA clearance.
TABLE 1. Patients characteristics in relation to DTPA clearance
Normal DTPA
(%)
Abnormal
DTPA (%)
% of total
abnormal
DTPA
% abnormal
DTPA of total
population
Sex Female 11 (46) 13 (54) 45 26
Male 10 (38) 16 (62) 55 32
Duration 10 years 12 (40) 18 (60) 62 36
4 10 years 9 (45) 11 (55) 38 22
Control Good 10 (48) 11 (52) 38 22
of diabetes Poor 11 (38) 18 (62) 62 36
Treatment Insulin 9 (47) 10 (53) 34 20
Oral 12 (37) 20 (63)* 66* 40*
*One patient was counted twice as he was on both oral therapy and insulin.
TABLE 2. Summary of clinical parameters of patients with
abnormal DTPA clearance*
Parameter Complicated
diabetes (n=17)
Uncomplicated
diabetes (n=12)
Age (years) 57?53+ 9?63 50?17+ 6?85
Duration of
Diabetes (years)
14?53+ 6?38 5?42+ 3?48
DTPA (t) 73?35+ 26?06 75?17+ 21?85
*Values expressed as mean+ S.D. The P-value was not
significant in these parameters between complicated and
uncomplicated cases.
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In the study of Caner et al. (10) the reported finding was
that there was a significant difference in the permeability
between the complicated diabetics and the normals, while
this difference does not exist between the normals and
diabetic patients without complications. Whilst we confirm
in our study that there is a significant delay of DTPA
clearance in diabetic compared to the normal non-smoking
population, this delay is not expressed in all diabetic
patients. This means that there are certain patients,
probably due to certain risk factors, who are more liable
to have pulmonary epithelial damage secondary to diabetes.
DTPA clearance may prove to be more sensitive than
carbon monoxide diffusion capacity in detecting early lung
involvement in complicated or uncomplicated diabetics.
The risk factors we tried to explore were age, sex,
duration of diabetes, control of blood sugar, presence or
absence of diabetic complications and presence or absence
of retinopathy, neuropathy and nephropathy indepen-
dently. The statistical analysis does not show statistically
significant differences, which most likely is due to the smallnumber of patients in the sample (especially when it is
broken down to each of the complications separately).
Looking at the odds ratios in Table 4 it can be seen that
certain factors are approaching statistical significance, for
example patients with established retinopathy and those
patients on insulin therapy, while lower numbers were
found in females, patients on oral hypoglycaemic medica-
tions, patients with tight glycaemic control and the absence
of diabetic complications (odds ratio of 0?4, 0?7, 0?8 and 0?3
respectively).
It is understandable that the longer the duration of
disease, the higher the chance of requiring insulin therapy
and the rate of complications, and probably the higher the
chance that the pulmonary epithelium will be deranged.
By increasing the sample size these differences will
probobly be shown more clearly. Pulmonary complications
are quite common in diabetic patients, especially infections
(Gram-negative infections and tuberculosis), and they are a
major cause of morbidity and mortality in such patients.
Microangiopathy may be the significant factor, which
contributes to the increased incidence of such infections.
It is known that the microangiopathy which starts before
diabetes is clinically overt (2). It may be significant to
identify patients at risk (diabetic patients, patients with
impaired GTT), possibly by DTPA clearance, earlier and
thereby try to prevent major diabetic pulmonary complica-
tions such as infections (specially pulmonary infections and
tuberculosis which are more prevalent in diabetic patients).
In conclusion, our preliminary results show delayed
99mTc-DTPA aerosol clearance in more than 50% of
diabetic patients studied. The aerosol clearance test may
be useful in the management of diabetic patients by
detecting probable early pulmonary epithelial affection.
DTPA clearance may also have a future role in predicting
the prognosis of diabetic patients by categorizing risk
factors, which may increase the mortality and morbidity in
the patient. A larger scale study is needed to verify the
significance of delayed aerosol clearance and the contribu-
tion of different risk factors to the effect of diabetes on the
lung.
TABLE 3. DTPA clearance in relation to diabetic complications
Normal
DTPA (%)
Abnormal
DTPA (%)
% of total
abnormal
DTPA
% abnormal
DTPA of total
population
Complication Present 14 (45) 17 (55) 59 34
(any type) Absent 7 (37) 12 (63) 41 24
Type of Retinopathy 10 (40) 15 (60) 52 30
complication Neuropathy 12 (48) 13 (52) 45 26
Nephropathy 10 (45) 12 (55) 41 24
TABLE 4. Level of risk for developing delayed DTPA
clearance in diabetic patients by various risk factors
Risk factor Odds ratio 95% confidence interval
Sex
Female 1?00
Male 0?372 0?0766–1?8153
Complication
Present 1?00
Absent 0?336 0?0148–7?6430
Neuropathy
Absent 1?00
Present 1?007 0?0688–14?7466
Retinopathy
Absent 1?00
Present 9?247 0?3523–242?7243
Nephropathy
Absent 1?00
Present 0?841 0?0914–7?7441
P-value was not significant in any of the above values.
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